Stock Analysis of Cidara Therapeutics Inc (CDTX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code CDTX
Close 11.21
Change -0.790 / 6.58 %
Volume 60758.00
Vol Change 14542.00 / 31.47 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Cidara Therapeutics Inc
PE (TTM)

-1.22

Very Poor
Price / Book

5.70

Very Poor
Price / Sales

0.696

Very Good
Piotroski F Score

2.0

Poor
Market Cap

51137.22 K

Enterprise Value

16659.22 K

ROA (TTM)

-45.72

Very Poor
ROE (TTM)

-468.73

Very Poor
Net Margin (TTM)

-57.21

Very Poor
Revenue

12.05 %

56541.00 K
Net Profit

3.01 %

-30697.00 K
Debt to Equity

-0.158

Very Poor
Altman Z Score

-9.54

Very Poor
Quick Ratio

0.812

Not Good
Cash Ratio

0.531

Not Good


Highs/Lows of Cidara Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week12.16 7.81 % 1.54 % 13.4410.8814-May-2417-May-24
Two Week12.51 10.39 % 3.42 % 14.120610.8807-May-2417-May-24
One Month14.444 22.39 % 5.60 % 14.99810.00418-Apr-2423-Apr-24
Three Month14.298 21.60 % 5.95 % 24.410.00403-Apr-2423-Apr-24
Six Months15.6 28.14 % 17.48 % 24.410.00403-Apr-2423-Apr-24
One year27.0 58.48 % 27.52 % 29.610.00423-May-2323-Apr-24
Two year9.66 16.05 % 29.70 % 42.09.222-Mar-2308-Dec-22
Five year40.4 72.25 % 85.46 % 29.60.423-May-2306-Jun-22


Technical View of Cidara Therapeutics Inc
RSI

38.03

Neutral
MACD

-0.759

Bullish
ADX

14.31

Neutral
Super Trend

15.09

Mild Bearish
Williams %R

-89.82

Mild Bullish
CCI

-110.21

Mild Bearish


EMA 5

12.08

Strong Bearish
EMA 15

12.66

Mild Bearish
EMA 50

13.98

Strong Bearish
EMA 100

14.70

Mild Bearish
SMA 100

14.57

Mild Bearish
SMA 200

15.86

Mild Bearish
SMA 5 / 20

12.34 / 12.32

Strong Bearish
SMA 15 / 50

12.52 / 14.76

Mild Bearish
SMA 50 / 200

14.76 / 15.86

Mild Bearish




Charts of Cidara Therapeutics Inc


Returns of Cidara Therapeutics Inc with Peers
Period / StockCDTXALGSBLRXHYPR
1 Week-7.81%-5.72%-1.84%13.05%
1 Mth-22.39%-12.52%2.99%-1.86%
3 Mth-21.60%5.92%-48.80%-19.54%
6mth-28.14%0.364%-62.13%-27.98%
1 Year-58.48%-42.14%-57.33%-30.77%
2 Year16.05%-40.13%-51.52%-68.99%
5 Years-72.25%--88.26%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Cidara Therapeutics Inc with Peers
Ratio / StockCDTXALGSBLRXHYPR
PE-1.22-270.26-8.03-1.52
P/B5.70372.7017.710.680
ROA-45.72-83.61-94.49-40.51
ROE-468.73-137.90-220.63-44.62
Debt To Equity-0.1580.03520.7790.0022
Revenue56541.00 K
12.05 % 		15529.00 K
11.66 % 		4800.00 K
% 		9770.00 K
43.38 %
Net Income-30697.00 K
3.01 % 		-87679.00 K
8.71 % 		-52461.00 K
177.98 % 		-46613.00 K
36.29 %


Technicals of Cidara Therapeutics Inc with Peers
Technical / StockCDTXALGSBLRXHYPR-
ADX14.3120.4133.4018.53
CMF-0.124-0.1560.082-0.315
MFI45.7847.6165.4558.09
RSI38.0337.1641.8953.89
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Cidara Therapeutics Inc

Address : 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121
Tel : 858 752 6170
URL : https://www.cidara.com
Code : CDTX, ISIN : US1717571079, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 15_Apr_2015
Employee Count : 69

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)